Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)‘s stock had its “overweight” rating reissued by Piper Jaffray Companies in a note issued to investors on Thursday. They currently have a $110.00 price target on the biopharmaceutical company’s stock, down from their prior price target of $126.00. Piper Jaffray Companies’ target price would suggest a potential upside of 49.27% from the company’s previous close.

Several other equities research analysts have also commented on the stock. Cowen and Company reiterated a “buy” rating and set a $100.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday, July 11th. Vetr lowered shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $71.50 price target on the stock. in a research note on Monday, May 15th. Jefferies Group LLC set a $102.00 price target on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, August 25th. Barclays PLC lifted their price target on shares of Alnylam Pharmaceuticals from $50.00 to $70.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 10th. Finally, Credit Suisse Group lifted their price target on shares of Alnylam Pharmaceuticals from $90.00 to $96.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 27th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $83.50.

Shares of Alnylam Pharmaceuticals (NASDAQ ALNY) traded up 1.60% during midday trading on Thursday, hitting $73.69. 1,280,125 shares of the stock were exchanged. The stock has a 50 day moving average price of $81.97 and a 200-day moving average price of $67.40. Alnylam Pharmaceuticals has a 12 month low of $31.38 and a 12 month high of $89.45. The company’s market cap is $6.76 billion.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.22) by $0.12. Alnylam Pharmaceuticals had a negative net margin of 670.81% and a negative return on equity of 45.53%. The firm had revenue of $15.93 million during the quarter, compared to analyst estimates of $23.86 million. During the same quarter in the previous year, the business posted ($1.05) earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was up 82.9% compared to the same quarter last year. On average, analysts predict that Alnylam Pharmaceuticals will post ($5.18) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/09/09/alnylam-pharmaceuticals-inc-alny-earns-overweight-rating-from-piper-jaffray-companies.html.

Large investors have recently modified their holdings of the company. First Manhattan Co. purchased a new stake in shares of Alnylam Pharmaceuticals in the first quarter valued at about $135,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Alnylam Pharmaceuticals in the first quarter valued at about $148,000. QS Investors LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 59.7% in the second quarter. QS Investors LLC now owns 2,408 shares of the biopharmaceutical company’s stock valued at $192,000 after acquiring an additional 900 shares in the last quarter. Westpac Banking Corp purchased a new stake in shares of Alnylam Pharmaceuticals in the first quarter valued at about $202,000. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of Alnylam Pharmaceuticals by 7.0% in the second quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock valued at $203,000 after acquiring an additional 167 shares in the last quarter. 94.27% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.